Eli Lilly's LY-2140023 for schizophrenia

Quote

Anonymous

Guest
"Analysts have hailed LY2140023 as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs." More importantly, patients on LY2140023 did not experience weight gain (Zyprexa patients did!), prolactin elevation or extrapyramidal side effects.

Steven Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, said, "All currently prescribed antipsychotics act on dopamine receptors. Lilly remains optimistic that the novel mechanism of compounds with the ability to reduce glutamate hyperactivity, such as our mGlu2/3 receptor agonist, will someday represent the next generation of breakthrough treatments for schizophrenia."
 


















Well considering placebo did better in the last trial (beat Zyprexa to..) I place this as highly unlikely to ever come to market. Plus in previous trials it wasn't nearly as effective as Zyprexa. This will be a dog product if it some how does make it. I love how the company hypes up the pipeline. We have nothing...
 






Anonymous said:
Well considering placebo did better in the last trial (beat Zyprexa to..) I place this as highly unlikely to ever come to market. Plus in previous trials it wasn't nearly as effective as Zyprexa. This will be a dog product if it some how does make it. I love how the company hypes up the pipeline. We have nothing...
Click to expand...

Why Lilly has the best Hypeline in the industry. And we have Mr. $$$$ Taurel to thank for it.
 






Anonymous said:
"Analysts have hailed LY2140023 as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs." More importantly, patients on LY2140023 did not experience weight gain (Zyprexa patients did!), prolactin elevation or extrapyramidal side effects.

Steven Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, said, "All currently prescribed antipsychotics act on dopamine receptors. Lilly remains optimistic that the novel mechanism of compounds with the ability to reduce glutamate hyperactivity, such as our mGlu2/3 receptor agonist, will someday represent the next generation of breakthrough treatments for schizophrenia."
Click to expand...

http://www.selleckchem.com/ProductDetail.asp?ProdId=S6001

Looks like high-potential stuff to me. Not cheap, but potent and selective for sure.
 






Anonymous said:
"Analysts have hailed LY2140023 as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs." More importantly, patients on LY2140023 did not experience weight gain (Zyprexa patients did!), prolactin elevation or extrapyramidal side effects.

Steven Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, said, "All currently prescribed antipsychotics act on dopamine receptors. Lilly remains optimistic that the novel mechanism of compounds with the ability to reduce glutamate hyperactivity, such as our mGlu2/3 receptor agonist, will someday represent the next generation of breakthrough treatments for schizophrenia."
Click to expand...

Don't get excited. Its just a code name for another Lilly drug.

Lilly have historically lied about their patient experiences
and have hidden the ones they don't want anyone to know about.
As a result you can bet the weight gain, the prolactin elevation and
the extrapyramidal side effects will begin to show through
once its approved and too late for anyone to do anything about it.

The whole world knows how Lilly works now so don't expect the
same rate of expansion and profits as Lilly have experienced in the
less enlightened and informed past.
 












Number 7 is correct. I used to work for a collaborator company. All the while Lilly was vigrously claiming no weight gain with Zyprexa, I was making 2 trips to Indy/month to discuss development of a combination product that would combine olanzapine with an appetite suppressant. I wouldn't be at all surprised if prosecutors in the Zyprexa lawsuits have found some Lilly patents on such a product, which would smash their claim that Lilly was unaware of any weight gain problem with Zyprexa.
 






mGlu2/3 Agonist Prodrug Phase III Business area: Bio-Medicines LY2140023 (mGlu2/3 Agonist Prodrug) is a chemical entity agonist of the metabotropic glutamate 2/3 receptors. LY2140023 is being studied as a monotherapy for the treatment of schizophrenia. LY2140023 is also being studied as an add-on therapy for schizophrenia (Phase II).
 






Under development by Eli Lilly, LY2140023 is a novel investigational agent for the treatment of schizophrenia. A member of a new class of antipsychotic drugs, LY2140023 is still in early stage clinical development. Nevertheless, analysts have hailed it as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs.
 






Since an earlier Phase II trial showed a positive response in 2007, Lilly is conducting an additional Phase II study, HBBM, to test the safety and efficacy of LY2140023.

Lilly initiated Phase III clinical trials on LY2140023 in March 2011.
 






I remember while on Cymbalta brand we looked at slides showing Merck's Substance P was an up and comer in antidepressant development--hence the development of this glutamate / muscarinic compound. Apparently it can knock a horse down in the smallest of Ph II doses, so let's make it a schizo drug! Way to go LRL. Shotgun anyone?
 






Anonymous said:
"Analysts have hailed LY2140023 as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs." More importantly, patients on LY2140023 did not experience weight gain (Zyprexa patients did!), prolactin elevation or extrapyramidal side effects.

Steven Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, said, "All currently prescribed antipsychotics act on dopamine receptors. Lilly remains optimistic that the novel mechanism of compounds with the ability to reduce glutamate hyperactivity, such as our mGlu2/3 receptor agonist, will someday represent the next generation of breakthrough treatments for schizophrenia."
Click to expand...

Oh, so there really WAS weight gain with Z!! Funny, I thought all these years that all they had to do was turn their refrigerator around towards the wall....
 






























Top Bottom
Back
Quote